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Abstract
Background: Examine 90-day postoperative mortality and its predictors following shoulder arthroplasty
Methods: We identified vital status of all adults who underwent primary shoulder arthroplasty (Total shoulder
arthroplasty (TSA) or humeral head replacement (HHR)) at the Mayo Clinic from 1976-2008, using the prospectively
collected information from Total Joint Registry. We used univariate logistic regression models to assess the
association of gender, age, body mass index, American Society of Anesthesiologist (ASA) class, Deyo-Charlson
comorbidity index, an underlying diagnosis and implant fixation with odds of 90-day mortality after TSA or HHR.
Multivariable models additionally adjusted for the type of surgery (TSA versus HHR). Adjusted Odds ratio (OR) with
95% confidence interval (CI) were calculated.
Results: Twenty-eight of the 3, 480 patient operated died within 90-days of shoulder arthroplasty (0.8%). In
multivariable-adjusted analyses, the following factors were associated with significantly higher odds of 90-day
mortality: higher Deyo-Charlson index (OR, 1.54; 95% CI:1.39, 1.70; p < 0.001); a diagnosis of tumor (OR, 16.2; 95%
CI:7.1, 36.7); and ASA class III (OR, 3.57; 95% CI:1.29, 9.91; p = 0.01) or class IV (OR, 13.4; 95% CI:2.44, 73.86; p =
0.003). BMI ≥ 30 was associated with lower risk of 90-day mortality (OR, 0.25; 95% CI:0.08, 0.78). In univariate
analyses, patients undergoing TSA had significantly lower 90-day mortality of 0.4% (8/2, 580) compared to 1% in
HHR (20/1, 411) (odds ratio, 0.22 (95% CI: 0.10, 0.50); p = 0.0003).
Conclusions: 90-day mortality following shoulder arthroplasty was low. An underlying diagnosis of tumor, higher
comorbidity and higher ASA class were risk factors for higher 90-day mortality, while higher BMI was protective.
Pre-operative comorbidity management may impact 90-day mortality following shoulder arthroplasty. A higher
unadjusted mortality in patients undergoing TSA versus HHR may indicate the underlying differences in patients
undergoing these procedures.
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Background
Shoulder arthroplasty is an effective surgical procedure
for the treatment of refractory shoulder pain due to end
stage shoulder disease due to osteoarthritis and other
causes. It is associated with improvement in shoulder
pain, function and quality of life. Total shoulder arthro-
plasty (TSA) and humeral head replacement (HHR;
shoulder hemi-arthroplasty) are the two most common
shoulder arthroplasty procedures [1]. The utilization of
shoulder arthroplasty is projected to increase by 192%
by 2015 [2].
Like any other surgical procedure, there is a small risk
of perioperative mortality aft e rs h o u l d e ra r t h r o p l a s t y .
T S Aa n dH H Ra r em o s t l ye l e c t i v ep r o c e d u r e s ,w h i c h
makes it critical to study and understand the mortality
risk with these procedures. Patients and surgeons need
this information to assess risk/benefit ratio and make an
informed decision and have realistic expectations from
shoulder arthroplasty. While estimates of mortality are
available, little is known regarding patient risk factors
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any medium, provided the original work is properly cited.for mortality after shoulder arthroplasty. In our recent
study that included patients up to year 2000, the 90-day
mortality after shoulder arthroplasty was 0.58% (17 of 2,
953) [3]. Smaller studies, which were likely underpow-
ered, and had shorter follow-up have reported lower
mortality: 30-day mortality of 0.4% in 793 TSA patient
from Veterans Affairs medical centers [4] and no in-
hospital deaths in 994 shoulder arthroplasties in a dis-
charge database from Maryland [5]. In a study of system
factors, lower surgeon volume was associated with
higher mortality following shoulder arthroplasty [6];
however no patient-level factors have been studied.
Mortality within 90-days of arthroplasty could be poten-
tially linked to surgery and/or its complications and is
of more interest to the surgeon and the patient, as
opposed to long-term mortality (1- or 5-year post-sur-
gery), which may indicate baseline mortality risk, rather
than related to the surgery. In this study, our aims were
to: (1) determine the risk factors and rate of 90-day
mortality following primary shoulder arthroplasty (TSA
or HHR); and (2) if data allowed, to assess whether mor-
tality differed by the type of procedure (TSA versus
HHR).
Methods
Data Source
Every patient undergoing shoulder arthroplasty at the
Mayo clinic is followed prospectively by the clinic’s
Total Joint Registry (originally for hip, but captures all
arthroplasties), which has captured every shoulder
arthroplasty since 1976 for occurrence of any compli-
cation including death [7]. The Total Joint Registry has
full-time trained registry staff that follow patient com-
plications using assessments from scheduled clinic fol-
low-up visits and in those failing to return for clinic
visits, using mailed questionnaires and telephone calls.
Mortality data (vital status and date of death) are
obtained from the medical records at the Mayo clinic
and other medical centers, Social Security Death Index
and/or verbal report of patient’s death by patient’s
spouse/significant other. Numerous high quality out-
comes studies have been published using Mayo Clinic
Total Joint Registry, including mortality studies in
patients with knee and hip arthroplasty [8,9]. The
study was approved by the Mayo Clinic Institutional
Review Board.
Study Population and Outcome
All adults who underwent either primary TSA or HHR
between January 1976 and December 2008 at the Mayo
clinic, Rochester, MN were included. There were no age
or diagnosis restrictions. The outcome of interest was
all-cause mortality within 90 days of primary TSA or
HHR.
Predictors of Interest
Our main aim was to assess the predictors of 90-day
mortality after primary shoulder arthroplasty. Antici-
pating a few deaths even with a 33-year data, we
planned a priori to perform combined analyses for
TSA and HHR, and adjust analyses for the type of sur-
gery (TSA versus HHR), since the indications of the
two procedures differ. We anticipated that the number
of deaths would be too small to analyze the TSA and
HHR separately. The predictors of interest included
the following:
(1) Demographics: gender; age, < 60, ≥60-70, > 70
[10];
(2) Clinical:
(a) Body Mass Index (BMI) as categorized < 25, 25-
29.9 and > 30 Kg/m
2;
(b) American Society of Anesthesiologist (ASA)
scale, categorized as I/II versus III/IV;
(c) Deyo-Charlson Index, a validated measure of
medical comorbidity [11], is a summative weighted
scale of 17 comorbidities (including cardiac, pul-
monary, renal, hepatic disease, diabetes, cancer,
HIV etc.), for example, conditions such as myocar-
dial infarction, dementia, peptic ulcer disease etc.
each get a score of “1"; diabetes with end-organ
damage, hemiplegia, renal disease, malignancy
each get a score of “2"; moderate-severe liver dis-
e a s eas c o r eo f“3"; metastatic solid tumor and
AIDS/HIV each get score of “6” - this was cate-
gorized as 0 or ≥1, since the median for this
population was zero;
(d) Diagnosis: categorized as rheumatoid arthritis,
osteoarthritis, rotator cuff disease, trauma, other; and
(3) Implant fixation (cemented versus not).
Statistical Analysis
Summary statistics were calculated for continuous and
categorical variables as means or proportions. For the
main aim assessing predictors of mortality, we assessed
univariate associations of predictors of interest (age,
g e n d e r ,B M I ,A S A ,D e y o - C h a r l s o n ,d i a g n o s i sa n d
implant fixation) with 90-day mortality using logistic
regression. For each predictor, we also performed multi-
variable-adjusted analyses by adjusting analyses for the
type of arthroplasty (TSA versus HHR) based on our
clinical prediction that arthroplasty type might be asso-
ciated with mortality. The objective of adjusting for the
type of surgery was to assess if each variable of interest
(age, gender, Deyo-Charlson comorbidity index, diagno-
sis and implant fixation) was independently associated
with the outcome, after adjusting for the effect of the
type of surgery. Since our main objective was to assess
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arthroplasty, the HHR and TSA groups were combined
for analyses. We decided not to perform additional ana-
lyses adjusted for multiple variables to avoid over-
adjusted models, since the total number of outcomes
was < 30. For analysis of the second aim of whether
type of surgery had an impact on mortality, univariate
associations of type of surgery with mortality were
assessed. We also examined each of the multivariable
analyses performed for main aim for significance of type
of surgery variable, since all models were simultaneously
adjusted for this variable. Odds ratios and 95% confi-
dence intervals are presented. A p-value < 0.05 was con-
sidered significant.
Results
Clinical and Demographic Characteristics
3, 490 patients who underwent 4, 019 shoulder
arthroplasties during 1976-2008 were included in this
study. Of these, 1, 431 (36%) underwent shoulder
hemi-arthroplasty and 2, 588 (64%) underwent TSA.
The mean age was 64 years and 56% were women
(Table 1).
90-day Mortality
28 of the 3, 480 patient operated died within 90-days of
shoulder arthroplasty (0.8% ) ,2 0a f t e rH H Ra n d8a f t e r
TSA. The 90-day mortality risk seemed similar across
time-periods: 0.4% (1/261) died during 1976-1980; 0.9%
during 1981-1990 (9/1, 016); 0.6% during 1991-2000 (7/
1, 219); and 0.7% during 2001-2008 (11/1, 495). Due to
the small number of events, we were unable to test for
the significance of time-trends in 90-day mortality.
Of the 20 HHR patients, 5 died between day 16 and
day 30, 6 died between day 31 and day 60, 9 died
between day 61 and day 90. Of the 8 TSA patients, 3
died between day 2 and day 30, 4 died between day 31
and day 60 and one died between day 61 and day 90.
No patients died within the first 24 hours after HHR or
TSA.
Predictors of 90-day Mortality
In univariate analyses, lower BMI and higher Deyo-
Charlson index were each associated with higher odds
of 90-day mortality after shoulder arthroplasty (Table 2).
ASA class 3 and class 4 were also associated with signif-
icantly increased risk of 90-day mortality after shoulder
Table 1 Clinical and socio-demographic characteristics of Study Cohort
Mean (standard deviation) or % (n)
3, 480 patients with 4, 019 shoulder arthroplasties (TSA or HHR)
Age in years 65 (13) [median 67, range 18 to 67]
Female/male 2, 250 (56%)/1769 (44%)
Deyo-Charlson index 1.0 (1.8)
Body Mass Index (BMI)
a 29 (6)
American Society of Anesthesiologist (ASA)
b
ASA Class I/II 1, 725 (57%)
ASA Class III 1, 281 (43%)
ASA Class IV 15 (1%)
Implant fixation
Cemented 3, 342 (83%)
Uncemented 677 (17%)
Underlying Diagnosis
c
Rheumatoid arthritis 685 (17%)
Trauma 867 (22%)
Tumor
d 182 (5%)
Osteoarthritis 1, 988 (49%)
Rotator cuff disease 177 (4%)
Other
e 120 (3%)
a BMI was available from 9/1/1987 to present on 3, 127 shoulders;
b ASA was available from 11/1/1988 to 2008 on 2, 317 shoulders
c Except for trauma, all other underlying diagnoses are associated with elective arthroplasty
dOf the 182 with underlying diagnosis of tumor, 135 (74%) had primary cancer and 47 (26%) had metastatic cancer.
e Other category for underlying diagnosis includes: avascular necrosis, ankylosing spondylitis, psoriatic arthritis, gout, Charcot arthropathy, dislocation, old injury,
prior history of septic arthritis
All numbers rounded to nearest whole number and therefore percents may not add to 100%
TSA, Total Shoulder Arthroplasty; HHR, Humeral Head Replacement
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adjusted for each variable of interest and the type of surgery (TSA versus hemiarthroplasty)
Univariate models Multivariable models adjusted for
surgery type
90 day
mortality
n/N
d (%)
Odds ratio (95% Confidence
interval)
univariate
p-value
Odds ratio (95% Confidence
interval)
p-
value
Gender
Female (n = 2, 250) 14/2, 236 (1%) 1.0 (ref) 1.0 (ref)
Male (n = 1, 769) 14/1, 755 (1%) 1.27 (0.61, 2.68) 0.52 1.50 (0.71, 3.17) 0.29
Age
≤ 60 (n = 1, 255) 6/1, 249
(0.5%)
1.0 (ref) 1.0 (ref)
61-70 (n = 1, 213) 6/1, 207
(0.5%)
1.04 (0.33, 3.22) 0.95 1.34 (0.43, 4.19) 0.62
≥ 70 (n = 1, 551) 16/1, 535 (1%) 2.17 (0.85, 5.56) 0.11 2.40 (0.94, 6.17) 0.07
Body Mass Index (BMI)
a
< 24.9 (n = 809) 13/796 (2%) 1.0 (ref) 1.0 (ref)
25-29.9 (n = 1, 094) 7/1, 087 (1%) 0.40 (0.16, 1.00) 0.05 0.46 (0.18, 1.16) 0.10
≥ 30 (n = 1, 224) 4/1, 220
(0.3%)
0.20 (0.07, 0.62) 0.005 0.25 (0.08, 0.78) 0.02
ASA class
b
ASA 1, 2 (n = 1, 725) 5/1, 720
(0.3%)
1.0 (ref) 1.0 (ref)
ASA 3 (n = 1, 248) 15/1, 233 (1%) 4.19 (1.52, 11.55) 0.006 3.57 (1.29, 9.91) 0.01
ASA 4 (n = 33) 2/31 (6%) 22.19 (4.15, 118.83) 0.0003 13.44 (2.44, 73.86) 0.003
Deyo-Charlson Index
Index = 0 (n = 2, 275) 3/2, 272
(0.1%)
1.0 (ref) 1.0 (ref)
Index ≥1 (n = 1, 744) 25/1, 719 (1%) 11.01 (3.32, 36.50) < 0.001 9.99 (3.01, 33.19) 0.0002
Diagnosis
RA, osteoarthritis, trauma and other
c
(n = 3, 837)
14/3823
(0.4%)
1.0 (ref) 1.0 (ref)
Tumor (n = 182) 14/168 (8%) 22.76 (10.68, 48.50) < 0.001 16.18 (7.10, 36.85) <
0.001
Diagnosis
RA, osteoarthritis, tumor and other
c (n
= 3152)
23/3152 (1%) 1.0 (ref) 1.0 (ref)
Trauma (n = 867) 5/867 (1%) 0.79 (0.30, 2.08) 0.63 0.52 (0.20, 1.40) 0.20
Cement
No cement (n = 677) 4/673 (1%) 1.0 (ref) 1.0 (ref)
Cement (n = 3342) 24/3, 318 (1%) 1.22 (0.42, 3.52) 0.72 2.81 (0.94, 8.39) 0.06
Significant p-value in multivariable model are in bold.
a BMI was available from 9/1/1987 to present on 3, 127 shoulders;
b ASA was available from 11/1/1988 to 2008 on 2, 317 shoulders
c Other includes the following diagnoses: tumor (n = 182); rest (n = 297) included avascular necrosis, ankylosing spondylitis, psoriatic arthritis, gout, Charcot
arthropathy, dislocation, old injury, prior history of septic arthritis
d Discrepancy in numbers was due to loss to follow-up of a few patients
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associated with significantly increased 90-day mortality
compared to all other diagnoses combined. We also
compared elective versus non-elective (trauma) cases.
There were no significant differences in risk of mortality
between trauma versus other diagnoses (elective).
In multivariable models that adjusted for the type of
arthroplasty (TSA versus hemiarthroplasty), higher
Deyo-Charlson index, ASA class 3 or class 4, an under-
lying diagnosis of tumor were each still significantly
associated with higher 90-day mortality; BMI ≥30 was
significantly associated with lower 90-day mortality,
compared to BMI < 25 kg/m
2 (Table 2).
The significance of associations of Deyo-Charlson
index or BMI with mortality did not change when these
variables were examined as continuous variables. Each
unit increase in BMI and Deyo-Charlson index was
associated with odds ratio of 0.91 (0.84, 0.99) (p = 0.02)
and 1.54 (1.39, 1.70) (p < 0.001) for 90-day mortality,
respectively, when simultaneously adjusted for the type
of surgery.
Differences between TSA and HHR
In univariate analyses, patients undergoing TSA had sig-
nificantly lower 90-day mortality of 0.4% (8/2, 580) com-
pared to 1% in HHR (20/1, 411) (odds ratio, 0.22 (95%
CI: 0.10, 0.50); p = 0.0003). In all multivariable models
that adjusted for each variable of interest, type of sur-
g e r y( T S Av e r s u sH H R )r e m a i n e das i g n i f i c a n tv a r i a b l e
associated with 90-day mortality, with two exceptions,
namely the models that adjusted for the Deyo-Charlson
index and the underlying diagnosis.
Discussion
In this study, we found that 90-day mortality following
primary shoulder arthroplasty was 0.8% using 33-year
data from a larger medical center. This is in agreement
with previous studies reporting 0.6% 90-day mortality
after shoulder arthroplasty [3] and with 0.4% 30-day
mortality following TSA in veterans [4].
Several associations noted in this study are novel and
deserve further discussion. Our observation of associa-
tion of higher comorbidity with higher 90-day mortality
following shoulder arthroplasty extends the recent
observation of association of Deyo-Charlson index with
in-hospital mortality following shoulder [12]. Future stu-
dies need to examine which comorbidities are associated
with this increased risk. It remains to be seen whether
intensive preoperative comorbidity management could
lead to reduction in 90-day mortality after shoulder
arthroplasty, a rare but feared complication of this elec-
tive procedure.
Our finding of association of higher BMI with lower
mortality following shoulder arthroplasty is novel. To
our knowledge, there is only one published study that
assessed association of BMI with mortality in arthro-
plasty cohort [13]. In a sample of total hip arthroplasty
patients, there was no association of BMI with a compo-
site end-point of mortality, readmission, re-operation or
intensive care unit admissions [13]. However, the end-
point was composite, not mortality. On the other hand,
several studies have shown that lower BMI was a risk
factor for postoperative complications after hernia sur-
gery [14], postoperative pulmonary complications after
cardiac surgery [15], major adverse cardiac events after
percutaneous coronary intervention [16] and postopera-
tive adverse cardiac adverse events after hip fracture
repair [17]. Studies in non-arthroplasty populations have
shown that low BMI is a risk for higher in-hospital post-
operative mortality [15] and 30-day mortality after cor-
onary artery bypass grafting [18]. The “obesity paradox”
with worse outcomes noted in patients with lower BMI
has also been reported in patients with heart failure
[19]. A systematic review of cohort studies of patients
with coronary artery disease found lower than normal
BMI was associated with higher total mortality and car-
diovascular mortality compared to patients with normal
BMI [20]. To our knowledge, our study is the first study
to observe this association in patients who underwent
shoulder arthroplasty. Underweight patients are likely to
have low caloric and functional reserve compared to
overweight/obese patents, which might make them more
vulnerable to complications and subsequent mortality,
especially in a stressful postoperative period after arthro-
plasty. It is also possible that obese people who survive
to old age (patients who commonly undergo shoulder
arthroplasty) have a survival advantage as compared to
non-obese and lean patients. Adipose tissue is consid-
ered a metabolic organ, and the underlying mechanisms
for this association need to be investigated further. This
emerging body of evidence suggests a protective role for
normal and/or higher BMI with regards to post-surgical
survival. We believe this needs further study.
It is not unexpected that 90-day mortality was higher
in patients with higher/worse ASA class. This intuitive
finding has not previously reported in shoulder arthro-
plasty patients. This mirrors similar findings in patients
undergoing knee arthroplasty [21]. A higher mortality
was also noted in patients with an underlying diagnosis
of cancer, which is intuitive.
We found that TSA was associated with lower mortal-
ity compared to HHR. This is at least partially due to
differences in indications for TSA versus HHR. The
mortality risk difference was significant in all multivari-
able models except two models that simultaneously
adjusted for: (1) comorbidity and surgery type and; (2)
underlying diagnosis and surgery type. This implies that
higher mortality in primary TSA patients compared to
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the underlying diagnoses between TSA and HHR
cohorts. This is an important observation that needs to
be accounted for in future studies comparing mortality
between TSA and HHR cohorts.
Our study has several limitations. BMI and ASA data
were not available for the entire study duration, since
these were captured starting in 1987/88. However, for
both variables, significant associations were detected
implying that we had adequate power to examine strong
associations. We included a large sample size, but found
only 28 events during the 33-year study period, which
may have led to type II error, i.e., missing a significant
association due to small sample size when such an asso-
ciation really existed. Due to a small sample size, the
multivariable models were only adjusted for the surgery
type; additional adjustment would have led to over-
adjusted models. Residual confounding is possible due
to cohort study design, despite our attempts to incorpo-
rate several important patient-level factors. It is unlikely
that any randomized study in arthroplasty will be large
enough to study mortality rates, therefore these analyses
are likely to be performed in cohort or case-control stu-
dies. The cohort characteristics are similar to those
reported in other studies, implying that findings from
our study may be generalizable to other settings. We
attempted review of medical records but were unable to
find the cause of death for most patients, related to one
or more of the following reasons: (1) Total joint registry
captures the date, but not cause of death; (2) most
shoulder arthroplasties, and therefore most deaths
occurred in patients referred to the medical center, for
whom the cause of death was not documented in medi-
cal records; (2) autopsy data were missing for most
patients.
Conclusions
In summary, we found that 90-day mortality following
primary shoulder arthroplasty was low at 0.80%. Several
patient-level factors, such as higher comorbidity, under-
lying diagnosis of tumor, higher/worse ASA class, lower
BMI were risk factors for 90-day mortality after primary
shoulder arthroplasty. Future studies need to examine if
optimization of preoperative comorbidity management
can further reduce the rare fatality after shoulder
arthroplasty.
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